Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

Marta Ciofi Degli Atti, Alessandra Anemona, Alberto Eugenio Tozzi, Paola Stefanelli, Anna Giammanco, Stefania Salmaso

Research output: Contribution to journalArticlepeer-review


The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21-40 months of age was evaluated. Vaccination was well-tolerated: fever ≥38°C was reported after 5% of administered doses and local reactions after 14-15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children > 1 year of age, catch-up vaccination campaigns could be considered in areas where pertussis whole-cell vaccination uptake has been low and where the number of susceptible children should be reduced to control pertussis circulation.

Original languageEnglish
Pages (from-to)2030-2035
Number of pages6
Issue number15-16
Publication statusPublished - Apr 9 1999


  • Acellular pertussis vaccines
  • Catch-up
  • Safety

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)


Dive into the research topics of 'Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age'. Together they form a unique fingerprint.

Cite this